[The outlook for the development of a vesicular meningococcal serogroup B vaccine].
Del'vig
A A
AA
Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia.
Semenov
B F
BF
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000276:immunology*; D002986:Clinical Trials as Topic; D018073:Haemophilus Vaccines / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D008585:Meningitis, Meningococcal / Q000517:prevention & control; D009345:Neisseria meningitidis / Q000276:immunology*; D017778:Vaccines, Combined / Q000009:adverse effects / Q000276:immunology
D000276:Adjuvants, Immunologic; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; D017778:Vaccines, Combined
Perspektivy razrabotki vezikuliarnoĭ meningokokkovoĭ vaktsiny serogruppy B.